Canada’s first national investigator-led menopause study invites eligible people to share experiences and help improve research, care, policy, and support.
Originally published via Source Article.
Blog
-
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended June 30, 2026 (“Fiscal Q3 2026”).
Originally published via Source Article.
-
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended June 30, 2026 (“Fiscal Q3 2026”).
Originally published via Source Article.
-
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended June 30, 2026 (“Fiscal Q3 2026”).
Originally published via Source Article.
-
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended June 30, 2026 (“Fiscal Q3 2026”).
Originally published via Source Article.
-
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended June 30, 2026 (“Fiscal Q3 2026”).
Originally published via Source Article.
-
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work
Originally published via Source Article.
-
HPQ and Novacium Deliver Custom-Configured Battery Packs to Three European Drone Manufacturers for Final-Stage Evaluation
HPQ and Novacium deliver 30 custom-configured battery packs to three European drone manufacturers for final-stage evaluation and potential integration.
Originally published via Source Article.
-
Ninepoint Partners Announces Ninepoint 2026 Short Duration Flow-Through Limited Partnership
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Ninepoint Partners LP (“Ninepoint”) is pleased to announce that the Ninepoint 2026 Short Duration Flow-Through Limited Partnership (the “Partnership”) has filed a preliminary prospectus (the “Prospectus”) in connection with its offering of limited partnership units (the “Units”). A receipt for the Prospectus has been issued by the securities regulatory authorities in each of the provinces and territories of Canada. The Units are being offered at a price per Unit of $25.00 with a minimum subscription of 100 Units ($2,500).
Originally published via Source Article.
-
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work
Originally published via Source Article.